Journal of Antimicrobial Chemotherapy, Vol 41, 103-106, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
H Tomizawa, K Tateda, S Miyazaki and K Yamaguchi
AM-1155, a novel fluoroquinolone, exhibited potent activity against
Streptococcus pneumoniae, including penicillin-resistant strains; the MIC90
for 48 clinical isolates was 0.25 mg/L. The antibacterial activity of
AM-1155 against S. pneumoniae was higher than that of levofloxacin (MIC90 1
mg/L) and comparable with that of sparfloxacin. The MIC90s of penicillin G
and erythromycin were 2 and > 4 mg/L, respectively. AM-1155 showed no
cross-resistance to penicillin or erythromycin. For experimental murine
pneumonia with S. pneumoniae intermediately resistant to penicillin, oral
administration of AM-1155 showed efficacy higher than that of levofloxacin
and equal to that of sparfloxacin. The efficacy of AM-1155 was also equal
to that of subcutaneous penicillin G administration at the same dosage.
ORIGINAL ARTICLES
Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Schaumann, G. Ackermann, B. Pless, M. C. Claros, and A. C. Rodloff In Vitro Activities of Gatifloxacin, Two Other Quinolones, and Five Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2783 - 2786. [Abstract] [Full Text] |
||||
